

Do Covid-19 Antibodies Provide Protection for Over 6 Months?

Deveci O* Department of Infectious Diseases and Clinical Microbiology, Batman Medical Park Hospital

Article Information

Article Type:	Letter to Editor	*Corresponding Author:	Citation:
Journal Type:	Open Access	Ozcan Deveci,	Deveci O (2021). Use of Traditional Medicines for Prevention and Treatment of Covid-19. A Cross-Sectional Survey in Four African Countries. J Corona Virus. 1(2); 1-8
Volume:	Issue: 2	Batman Medical Park Hospital, Department of Infectious Diseases and Clinical Microbiology, Batman, Turkey,	
Manuscript ID:	JCV-v1-1118	E-mail: ozcandeveci1@hotmail.com	
Publisher:	Science World Publishing		
Received Date:	31 May 2021		
Accepted Date:	10 June 2021		
Published Date:	15 June 2021		

Copyright: © 2021, Deveci O, *et al.*, This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 international License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

DEAR EDITOR

COVID-19 is a SARS -CoV-2 type novel contagious human disease that affected several countries worldwide. Serological tests are particularly valuable in epidemiological studies that aim to determine the immunity levels of the affected population, including both diagnosed and asymptomatic individuals. SARS -Cov-2 virus includes 4 structural proteins. Among these, S and N proteins are the most studied antigens. All advancing techniques focused on detection of IgM and IgG antibodies [1,2]. Due to the short half-life of IgM antibodies (5-6 days) and the long half-life of IgG antibodies (21 days), IgM count decreases to undetectable levels, while IgG count is maintained further. Certain studies demonstrated that individuals who survived the COVID-19 infection continued to produce antibodies against significant sections of the virus for several months. However, the duration that these antibodies remain active and whether they are sufficient to protect against reinfection remains unclear. In a study, it was observed that COVID-19 antibodies protected most individuals from re-infection for six months [3]. In the antibody test we conducted on several healthcare professionals who were COVID-19-positive more than 6 months ago in our hospital demonstrated that the positivity continued and even increased in certain cases.

The conducted antibody test is an in vitro immunochemistry test that qualitatively identifies SARS -CoV-2 antibodies (including IgG) in human serum and plasma. The test was developed as an assistant in the determination of the immune system response to SARS -CoV-2. However, further comprehensive studies are required to determine long-term immunity. We hope this letter would serve as a pioneer for future studies

COMPETING INTERESTS DISCLAIMER

Authors have declared that no competing interests exist. The products used for this research are commonly and predominantly use

products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors

REFERENCES

1. A.La Marca, M. Capuzzo, T. Paglia, L. Roli, T. Trenti, S.M.J.R.b.o. Nelson, Testing for SARS-CoV-2 (COVID-19): A systematic review and clinical guide to molecular and serological in-vitro diagnostic assays. *Reprod Biomed Online*. 2020; 14: 483-99.
2. B.Meyer, C. Drosten, M.A. Müller, Serological assays for emerging coronaviruses: Challenges and pitfalls, *Virus Res*. 2014; 194: 175-83.
3. Sheila F Lumley, Denise O'Donnell, Nicole E Stoesser, Philippa C Matthews, Alison Howarth, Stephanie B Hatch, et al. Oxford University Hospitals Staff Testing Group, Derrick W Crook, Anne-Marie O'Donnell, Christopher P Conlon, Koen B Pouwels, A Sarah Walker, Tim EA Peto, Susan Hopkins, Timothy M Walker, Katie Jeffery, David W Eyre. Antibodies to SARS-CoV-2 are associated with protection against reinfection. medRxiv preprint.